27 May

What Analysts Recommend for Medtronic after Its Q4 Results

WRITTEN BY Margaret Patrick

Stock price movements

On May 23, Medtronic (MDT) reported its fiscal 2019 fourth-quarter earnings results. The company reported revenue of $8.15 billion in the quarter, a YoY (year-over-year) rise of 0.02% on a reported basis, a YoY rise of 3.6% on an organic basis, and $25.25 million higher than analysts’ consensus revenue estimate.

The company reported revenue of $30.56 billion in fiscal 2019, a YoY rise of 2.0% on a reported basis. According to its fourth-quarter earnings press release, its revenue was negatively affected by its divestiture of certain businesses to Cardinal Health and unfavorable foreign exchange movements in fiscal 2019.

What Analysts Recommend for Medtronic after Its Q4 Results

In the fourth quarter, Medtronic reported non-GAAP (generally accepted accounting principles) EPS of $1.54, a YoY rise of 8.45% and $0.07 higher than the consensus estimate. The company reported non-GAAP EPS of $5.22 in fiscal 2019, a YoY rise of 9.43% and ahead of its guidance of $5.14–$5.16.

Following the release of its results, Medtronic closed at $91.64, 3.24% higher than its previous day’s close. On May 24, the company closed at $93.03, 1.52% higher than its previous close, 13.92% higher than its 52-week low of $81.66, and 7.11% lower than its 52-week high of $100.15. The company’s market cap was $124.92 billion, and its PE, forward PE, PE-to-growth, price-to-sales, price-to-book, and price-to-cash ratios were 24.81x, 15.71x, 3.47x, 4.09x, 2.51x, and 13.66x, respectively.

Medtronic’s 14-day relative strength index is currently 71.09. Its number of outstanding shares is 1.34 billion, while its short float ratio is 0.72%.

Analysts’ recommendations and target prices

Wall Street analysts expect an upside potential of 10.80% for Medtronic based on the company’s closing price on May 24. Analysts first raised the company’s 12-month consensus target price from $103.23 in February to $103.38 in March but then reduced it to $103.28 in April and $102.33 in May.

Of the 27 analysts covering Medtronic, six have given it “strong buys,” 11 have given it “buys,” and ten have given it “holds.” The highest and lowest target price estimates for Medtronic are $121 and $84, respectively.

Latest articles

US crude oil production has more than doubled since 2009 and grew by 1.1% over the last year. Currently, there are 133 operable refineries in the US.

The cannabis industry is fighting against the ongoing US-China trade war and recessionary worries, which have hurt valuations across the global market.

Higher revenues, increased ticket prices, and lower fuel costs are likely to drive American Airlines' Q3 earnings higher despite its Boeing MAX woes.

HEXO plans to report its Q4 earnings before the market opens on October 24. October has been tough for Hexo, with its stock falling 31.2% as of October 18.

Today, Advanced Micro Devices (AMD) rose 4% to over $32, making it one of the top Nasdaq gainers. Morgan Stanley raised its price target for AMD stock.

Early in 2019, President Donald Trump warned that China could overtake the US as a global power. He vowed that this would not happen under his leadership.